Orphai acquisition and up to $187M financing ignite Quince

 

Orphai acquisition and up to $187M financing ignite QNCX 22.61% premarket surge.

• Quince Therapeutics announced the acquisition of Orphai Therapeutics, adding a pulmonary disease pipeline.
• Deal paired with up to $187 million private placement to fund clinical advancement.
• Positive Phase 2 data reported for assets in pulmonary arterial hypertension (PAH) and PH-ILD.
• Represents major strategic pivot after January 2026 Phase 3 failure in Ataxia-Telangiectasia and subsequent restructuring.
• Earlier milestones included March 2026 EIB debt settlement ($16.4M retired for $5.5M) and April reverse split.
• Announcement triggered strong retail and investor interest in the newly capitalized shell with clinical assets.
• Premarket volume elevated as traders reacted to the fresh pipeline and substantial capital raise.

https://finviz.com/quote?t=QNCX&p=d